GlycoMeds

GlycoMeds, Inc. was a pioneering biotechnology company focused on the development of carbohydrate-based therapeutics, specifically targeting the selectin family of adhesion molecules. Founded in the early 1990s, the company leveraged its expertise in glycobiology to design small molecule and peptide inhibitors intended to treat inflammatory conditions such as asthma, psoriasis, and reperfusion injury. Its research centered on blocking the interaction between selectins and their carbohydrate ligands to prevent the migration of white blood cells to sites of inflammation. In 1998, GlycoMeds was acquired by Medarex, Inc., which sought to integrate GlycoMeds' carbohydrate technology with its own monoclonal antibody platform. The company's legacy contributed to the broader field of glycomimetics and the development of anti-inflammatory drug candidates.